Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494987 | 0.86 | SMN1; SMN2 (0.31) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL179267 | 0.75 | HDAC8 (0.35) | SMN1; SMN2L3MBTL1HDAC8HSP90AA1KDM4E | |
| SCHEMBL30471955 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL26833445 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL26833401 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL31424844 | 0.74 | — | — | |
| SCHEMBL12238625 | 0.74 | SMN1; SMN2 (0.33) | SMN1; SMN2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6587339 | 0.73 | KDM4E (0.36) | HDAC8HSP90AA1KDM4EALDH1A1KMT2A | |
| SCHEMBL31175998 | 0.73 | HDAC8 (0.33) | HDAC8HSP90AA1KDM4EALDH1A1KMT2A | |
| SCHEMBL31194454 | 0.73 | HDAC8 (0.33) | HDAC8HSP90AA1KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | ACLARIS THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024249642-A1 | EGFR INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| US-20230242505-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | ACLARIS THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| CN-109195968-B | Fused pentacyclic imidazole derivatives as modulators of TNF activity | UCB生物制药私人有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3617195-A1 | NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES | Mochida Pharmaceutical Co., Ltd. (JP) | 2020-03-04 | — | — | EP | disclosed |
| CN-110461842-A | FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL | 2019-11-15 | — | — | CN | disclosed |
| CN-107108672-B | Condensed five rings imdazole derivatives | UCB生物制药私人有限公司 | 2019-11-08 | — | — | CN | disclosed |
| CN-105814043-B | Triazolopyridine derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2019-05-17 | — | — | CN | disclosed |
| CN-105814049-B | Fused tricyclic imdazole derivatives as TNF active regulator | UCB生物制药私人有限公司 | 2019-03-12 | — | — | CN | disclosed |
| EP-1558571-B1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7709528-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-20060287393-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2006-12-21 | — | — | US | disclosed |
| US-7129268-B2 | Peroxisome proliferator activated receptor-active arylene acetic acid derivatives | NOVO NORDISK A/S (DK) | 2006-10-31 | — | — | US | disclosed |
| EP-1558571-A1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| EP-1558572-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | disclosed |
| US-20050080115-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-04-14 | — | — | US | disclosed |
| US-20050070583-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2005-03-31 | — | — | US | disclosed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037775-A1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242505-A1 | PROCESS, COMPOSITIONS, AND CRYSTALLINE FORMS OF SUBSTITUTED PYRIDINONE-PYRIDINYL COMPOUNDS | MAPK6, MAPK1, MAPK8 | SMN1; SMN2 4188/4885L3MBTL1 4442/4885HDAC8 1893/4885 |
| US-20060287393-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | SMN1; SMN2 2907/4885L3MBTL1 4857/4885HDAC8 1670/4885 |
| US-20050070583-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | SMN1; SMN2 2907/4885L3MBTL1 4857/4885HDAC8 1670/4885 |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DUSP2, MKNK2, DUSP22 | SMN1; SMN2 3384/4885L3MBTL1 4657/4885HDAC8 513/4885 |
| US-20050080115-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | SMN1; SMN2 2907/4885L3MBTL1 4857/4885HDAC8 1670/4885 |
| US-12616696-B2 | Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one | MALT1, SSB, BCL9 | SMN1; SMN2 2775/4885L3MBTL1 3387/4885HDAC8 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.